AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04209348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity). Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.
Study NCT04209348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin. No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
Study NCT02344615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NS-guided infraclavicular block
Description: Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
Study NCT02344615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided infraclavicular block
Description: Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
Study NCT03539354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary spinal cord stimulation
Description: Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
Study NCT03539354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: Standart coronary artery bypass grafting procedure.
Study NCT03539354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Description: Standart coronary artery bypass grafting procedure.
Study NCT03539354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B-blockers
Description: Standart b-blocker therapy will be administered in each group for AF prophylactics
Study NCT03539354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-blockers
Description: Standart b-blocker therapy will be administered in each group for AF prophylactics
Study NCT00537784 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous platelets
Description: Local injection 10mL, about 2.5 x 10E10 platelets.
Study NCT00537784 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: no injection
Study NCT00074438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose
Study NCT00074438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose
Study NCT00074438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study NCT02214706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
Study NCT02214706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erbium yag laser
Description: Er:Yag laser ablation of the stratum corneum
Study NCT02214706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser
Study NCT03097978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial system
Description: Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
Study NCT03097978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC arm system
Description: Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
Study NCT03097978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Control
Description: Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
Study NCT03097978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pattern Recognition
Description: Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
Study NCT03032809 — intervention group
Intervention type: OTHER
Intervention: Vessel Wall MR imaging
Description: Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
Study NCT02668757 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HeartHab application intervention
Description: The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
Study NCT03502200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL
Description: Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
Study NCT03502200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
Study NCT01711099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy
Study NCT02709707 — intervention group
Intervention type: DEVICE
Intervention: Blood glucose monitor
Study NCT02121639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02121639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Study NCT04426357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
Study NCT04426357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-64417184
Description: Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
Study NCT03855540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECHOcardiography
Description: ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease
Study NCT03855540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood samples for plasmatic biomarkers
Description: 1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499
Study NCT03855540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Athens insomnia scale questionnaire
Description: Athens insomnia scale questionnaire
Study NCT03855540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG Holter monitor
Description: Patient receives ECG Holter monitor if included to the control group
Study NCT03855540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG event recorder
Description: Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
Study NCT00599677 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
Study NCT00599677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
Study NCT01649102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)
Description: A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard
Study NCT03670602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
Study NCT03670602 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Check in
Description: Participants will be asked to access the electronic app at the same rate as the experimental group (e.g. daily). Participants will receive behavioral weight loss treatment including The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, and finding behavioral substitutes for highly reinforcing food.
Study NCT00623246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET
Description: MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
Study NCT00623246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ED
Description: ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
Study NCT00074438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Intravenous repeating dose
Study NCT00074438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: Intravenous repeating dose
Study NCT00074438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT02239627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid
Study NCT02239627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT01942473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated FiO2 Control
Description: Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
Study NCT01753102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: one tablet will be inserted daily for 14 days
Study NCT01753102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol
Description: one tablet will be inserted daily for 14 days
Study NCT01753102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: one tablet will be inserted daily for 14 days
Study NCT00979069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic group
Description: 12 weeks of aerobic exercise 3 times a week
Study NCT00240227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: FDA approved medication for hypertension
Study NCT00240227 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study NCT04155853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interposition Arthroplasty
Description: A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
Study NCT04155853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hematoma and Distraction Arthroplasty
Description: A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
Study NCT03404609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 by MagVenture
Description: Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
Study NCT03538431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone is an atypical anxiolytic medication.
Study NCT04112524 — intervention group
Intervention type: DEVICE
Intervention: App
Description: * Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~* AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices.
Study NCT00287651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile IV Insulin
Description: Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
Study NCT01071785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: guar gum
Description: guar gum 10g/day for six weeks
Study NCT03851666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12 weeks daily administration Cereal 1
Description: The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams.
Study NCT03851666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks daily administration Cereal 2
Description: The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams.
Study NCT03851666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12 weeks daily administration Placebo
Description: The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.
Study NCT03338920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan nasal powder
Description: nasal powder administered via nosepiece
Study NCT03338920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose monohydrate powder administered via nosepiece
Study NCT02732496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training (TCT)
Description: The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
Study NCT02732496 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Youth Appropriate Online Games
Description: Engaging games not designed to improve cognition.
Study NCT02274233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Study NCT01287208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: The activity monitor is an accelerometer that records steps, distance, calories, and sleep
Study NCT01287208 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Activity device
Description: Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
Study NCT01906138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SENSIMED Triggerfish®
Description: All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
Study NCT02437526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic treatment interruption
Study NCT01399645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide-metformin vs insulin-metformin
Description: Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU.
Study NCT00287651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effects of Pulsatile IV Insulin on Diabetic Retinopathy
Description: Control Patients are not given pulsatile intravenous insulin therapy during the study.
Study NCT00287651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effects of Pulsatile IV Insulin on Diabetic Retinopathy
Description: Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
Study NCT00837928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
Study NCT00837928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
Study NCT00837928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Brain Metastases
Description: Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
Study NCT00837928 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)